Diffuse Large B-Cell Clinical Trial Analysis: Key Insights into Rich Pipeline Featuring 70+ Companies and 75+ Therapies
Stay ahead with the latest insights! Download DelveInsight's comprehensive Diffuse Large B-Cell Lymphoma Pipeline Report to explore emerging therapies, key Diffuse Large B-Cell Lymphoma Companies, and future Diffuse Large B-Cell Lymphoma treatment landscapes @ Diffuse Large B-Cell Lymphoma Pipeline Outlook Report
Key Takeaways from the Diffuse Large B-Cell Lymphoma Pipeline Report
In June 2025, Genmab announced a study will assess how safe and effective epcoritamab plus lenalidomide (E-Len) is compared to rituximab plus gemcitabine and oxaliplatin (R-GemOx) )in treating adult participants with relapsed or refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL). Adverse events and change in disease condition will be assessed.
In June 2025, Mitsubishi Tanabe Pharma Corporation conducted a phase I/II Open-Label Study of MT-2111 in Patients With Relapsed/Refractory DLBCL.
DelveInsight's Diffuse Large B-Cell Lymphoma pipeline report depicts a robust space with 70+ active players working to develop 75+ pipeline therapies for Diffuse Large B-Cell Lymphoma treatment.
The leading Diffuse Large B-Cell Lymphoma Companies such as Miltenyi Biomedicine, Adicet Bio, VelosBio, Novartis Pharmaceuticals, Sanofi, Eisai Co, Schrodinger, Sana Biotechnology, Ranok Therapeutics, Monte Rosa Therapeutic, Otsuka Pharmaceutical, OncoNano Medicine, Regeneron Pharmaceuticals, Hoffmann-La Roche, Celgene, Nurix Therapeutics, NovalGen, Nektar Therapeutics, Genentech, CSPC ZhongQi Pharmaceutical Technology and others.
Promising Diffuse Large B-Cell Lymphoma Therapies such as Ibrutinib, Bendamustine, Rituximab, R-miniCHOP, Selinexor, Tafasitamab, Lenalidomide, and others.
Discover how the Diffuse Large B-Cell Lymphoma treatment paradigm is evolving. Access DelveInsight's in-depth Diffuse Large B-Cell Lymphoma Pipeline Analysis for a closer look at promising breakthroughs @ Diffuse Large B-Cell Lymphoma Clinical Trials and Studies
Diffuse Large B-Cell Lymphoma Emerging Drugs Profile
Brentuximab vedotin: Pfizer
Brentuximab vedotin (Adcetris) is an anti-neoplastic agent. It is indicated for the treatment of patients with Classical Hodgkin lymphoma (HL) after failure of autologous hematopoietic stem cell transplantation (auto-HSCT) or after failure of at least two prior multi-agent chemotherapy regimens in patients who are not auto-HSCT candidates. Adcetris is also indicated for the treatment of adult patients with CD30+ Hodgkin lymphoma at increased risk of relapse or progression following autologous stem cell transplant (ASCT), also indicated for the treatment of adult patients with relapsed or refractory systemic anaplastic large cell lymphoma, for the treatment of adult patients with primary cutaneous anaplastic large cell lymphoma (pcALCL) and CD30-expressing mycosis fungoides (MF) who have received prior systemic therapy, for the treatment of adult patients with relapsed or refractory CD30+ cutaneous T- cell lymphoma (CTCL) after at least 1 prior systemic therapy. Adcetris is indicated for the first-line pediatric treatment for CD30-positive Hodgkin lymphoma. Currently, the drug is in Phase III stage of its clinical trial for the treatment of Diffuse Large B Cell Lymphoma.
THOR-707: Sanofi
THOR-707 is a precisely PEGylated version of IL-2, where the PEG chain is attached to a novel amino acid inserted at a location on IL-2 that prevents it from engaging the alpha-receptor and binding to immune receptors that cause drug toxicities (IL-2R-alpha, CD25). The engineered IL-2 retains near-native binding to the beta-gamma receptors that selectively expand tumor-killing T effector cells and Natural Killer (NK) cells without the alpha-mediated immunosuppressive effects of regulatory T cells or eosinophil-mediated vascular leak syndrome. Currently, the drug is in Phase II stage of its clinical trial for the treatment of Diffuse Large B Cell Lymphoma.
Abexinostat: Xynomic Pharmaceuticals
Abexinostat (Xynomic Pharmaceuticals) is a broad histone deacetylase (HDAC) inhibitor. HDAC enzymes (also known as lysine deacetylase) cleave acetyl groups from N-acetyl lysine amino acids on a histone. HDAC inhibition leads to highly acetylated histones and chromatin reshaping. In addition to altering histone acetylation, HDAC inhibitors can also influence the degree of acetylation on non-histone proteins, increasing or repressing their activity. Currently, the drug is in Phase II stage of its clinical trial for the treatment of Diffuse Large B-cell lymphoma.
RNK05047: Ranok Therapeutics
RNK05047 is a first-in-class, small-molecule, tumor- and BRD4-selective protein degrader that was discovered and developed using Ranok's proprietary approach to targeted protein degradation, CHAMPTM. The bromodomain transcription factor BRD4 is a key regulator of oncogenes such as MYC and BCL2 and is involved in diverse cancer types. CHAMP-1 is a Phase I/II trial of RNK05047 currently underway in the US that will assess its safety, tolerability, and pharmacokinetics, and also includes measures of anti-tumor activity and pharmacodynamics readouts as secondary endpoints.
BMF-219: Biomea Fusion
BMF-219 is an oral investigational covalent menin inhibitor. Data suggests that optimized covalent inhibitors can provide deeper inhibition while being better tolerated than some conventional reversible inhibitors. BMF-219 is being developed for genetically defined AML, ALL, DLBCL, MM and CLL patients. BMF-219 blocks the interaction of menin and MLL (AML, ALL), and limits the activity and/or expression of NPM1, MYC, HOX, and MEIS1, all known drivers of oncogenic proliferation and survival. Currently, the drug is in Phase I stage of its clinical trial for the treatment of Diffuse Large B Cell Lymphoma.
ADI-001: Adicet Bio
ADI-001 is an investigational allogeneic gamma delta CAR T cell therapy being developed as a potential treatment for relapsed or refractory B-cell NHL. ADI-001 targets malignant B-cells via an anti-CD20 CAR and via the gamma delta innate and T cell endogenous cytotoxicity receptors. Gamma delta T cells engineered with an anti-CD20 CAR have demonstrated potent anti-tumor activity in preclinical models, leading to long-term control of tumor growth. In April 2022, ADI-001 was granted Fast Track Designation by the FDA for the potential treatment of relapsed or refractory B-cell NHL. Currently, the drug is in Phase I stage of its clinical trial for the treatment of Diffuse Large B Cell Lymphoma.
The Diffuse Large B-Cell Lymphoma pipeline report provides insights into
The report provides detailed insights about companies that are developing therapies for the treatment of Diffuse Large B-Cell Lymphoma with aggregate therapies developed by each company for the same.
It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Diffuse Large B-Cell Lymphoma Treatment.
Diffuse Large B-Cell Lymphoma Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
Diffuse Large B-Cell Lymphoma Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Diffuse Large B-Cell Lymphoma market.
Get a detailed analysis of the latest innovations in the Diffuse Large B-Cell Lymphoma pipeline. Explore DelveInsight's expert-driven report today! @ Diffuse Large B-Cell Lymphoma Unmet Needs
Diffuse Large B-Cell Lymphoma Companies
Miltenyi Biomedicine, Adicet Bio, VelosBio, Novartis Pharmaceuticals, Sanofi, Eisai Co, Schrodinger, Sana Biotechnology, Ranok Therapeutics, Monte Rosa Therapeutic, Otsuka Pharmaceutical, OncoNano Medicine, Regeneron Pharmaceuticals, Hoffmann-La Roche, Celgene, Nurix Therapeutics, NovalGen, Nektar Therapeutics, Genentech, CSPC ZhongQi Pharmaceutical Technology and others.
Diffuse Large B-Cell Lymphoma pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
Oral
Intravenous
Subcutaneous
Parenteral
Topical
Diffuse Large B-Cell Lymphoma Products have been categorized under various Molecule types such as
Recombinant fusion proteins
Small molecule
Monoclonal antibody
Peptide
Polymer
Gene therapy
Download DelveInsight's latest report to gain strategic insights into upcoming Diffuse Large B-Cell Lymphoma Therapies and key Diffuse Large B-Cell Lymphoma Developments @ Diffuse Large B-Cell Lymphoma Market Drivers and Barriers, and Future Perspectives
Scope of the Diffuse Large B-Cell Lymphoma Pipeline Report
Coverage- Global
Diffuse Large B-Cell Lymphoma Companies- Miltenyi Biomedicine, Adicet Bio, VelosBio, Novartis Pharmaceuticals, Sanofi, Eisai Co, Schrodinger, Sana Biotechnology, Ranok Therapeutics, Monte Rosa Therapeutic, Otsuka Pharmaceutical, OncoNano Medicine, Regeneron Pharmaceuticals, Hoffmann-La Roche, Celgene, Nurix Therapeutics, NovalGen, Nektar Therapeutics, Genentech, CSPC ZhongQi Pharmaceutical Technology and others.
Diffuse Large B-Cell Lymphoma Therapies - Ibrutinib, Bendamustine, Rituximab, R-miniCHOP, Selinexor, Tafasitamab, Lenalidomide, and others.
Diffuse Large B-Cell Lymphoma Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
Diffuse Large B-Cell Lymphoma Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
Which companies are leading the race in Diffuse Large B-Cell Lymphoma drug development? Find out in DelveInsight's exclusive Diffuse Large B-Cell Lymphoma Pipeline Report—access it now! @ Diffuse Large B-Cell Lymphoma Emerging Drugs and Major Companies
Table of Content
Introduction
Executive Summary
Diffuse Large B-Cell Lymphoma: Overview
Pipeline Therapeutics
Therapeutic Assessment
Diffuse Large B-Cell Lymphoma– DelveInsight's Analytical Perspective
Late Stage Products (Phase III)
Brentuximab vedotin: Pfizer
Drug profiles in the detailed report…..
Mid Stage Products (Phase II)
THOR-707: Sanofi
Drug profiles in the detailed report…..
Early Stage Products (Phase I)
ADI-001: Adicet Bio
Drug profiles in the detailed report…..
Preclinical and Discovery Stage Products
Drug name: Company name
Drug profiles in the detailed report…..
Inactive Products
Diffuse Large B-Cell Lymphoma Key Companies
Diffuse Large B-Cell Lymphoma Key Products
Diffuse Large B-Cell Lymphoma- Unmet Needs
Diffuse Large B-Cell Lymphoma- Market Drivers and Barriers
Diffuse Large B-Cell Lymphoma- Future Perspectives and Conclusion
Diffuse Large B-Cell Lymphoma Analyst Views
Diffuse Large B-Cell Lymphoma Key Companies
Appendix
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 09650213330
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/diffuse-large-b-cell-lymphoma-pipeline-insight
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Globe and Mail
2 hours ago
- Globe and Mail
Nvidia and AMD to pay U.S. 15% of China chip sale revenues, official says
Nvidia NVDA-Q and AMD AMD-Q have agreed to give the U.S. government 15 per cent of revenue from sales to China of advanced computer chips like Nvidia's H20 that are used for artificial intelligence applications, a U.S. official told Reuters on Sunday. U.S. President Donald Trump's administration halted sales of H20 chips to China in April, but Nvidia last month announced the U.S. said that it would allow the company to resume sales and it hoped to start deliveries soon. Another U.S. official said on Friday that the Commerce Department had begun issuing licenses for the sale of H20 chips to China. When asked if Nvidia had agreed to pay 15 per cent of revenues to the U.S., a Nvidia spokesperson said in a statement, 'We follow rules the U.S. government sets for our participation in worldwide markets.' The spokesperson added: 'While we haven't shipped H20 to China for months, we hope export control rules will let America compete in China and worldwide.' AMD did not respond to a request for comment on the news, which was first reported by the Financial Times earlier on Sunday. The U.S. Department of Commerce did not immediately respond to a request for comment. The Financial Times said the chipmakers agreed to the arrangement as a condition for obtaining the export licenses for their semiconductors, including AMD's MI308 chips. The report said the Trump administration had yet to determine how to use the money. 'It's wild,' said Geoff Gertz, a senior fellow at Center for New American Security, an independent think tank in Washington, D.C. 'Either selling H20 chips to China is a national security risk, in which case we shouldn't be doing it to begin with, or it's not a national security risk, in which case, why are we putting this extra penalty on the sale?' U.S. Commerce Secretary Howard Lutnick said last month the planned resumption of sales of the AI chips was part of U.S. negotiations with China to get rare earths and described the H20 as Nvidia's 'fourth-best chip' in an interview with CNBC. Lutnick said it was in U.S. interests to have Chinese companies using American technology, even if the most advanced was prohibited from export, so they continued to use an American 'tech stack.' The U.S. official said the Trump administration did not feel the sale of H20 and equivalent chips was compromising U.S. national security. The official did not know when the agreement would be implemented or exactly how, but said the administration would be in compliance with the law. Alasdair Phillips-Robins, who served as an adviser at the Commerce Department during former president Joe Biden's administration, criticized the move. 'If this reporting is accurate, it suggests the administration is trading away national security protections for revenue for the Treasury,' Phillips-Robins said.
Globe and Mail
18 hours ago
- Globe and Mail
Thinking of Buying Alibaba Stock? Here's 1 Green Flag and 1 Red Flag.
Key Points AI cloud could be the answer to Alibaba's next phase of growth. But core e-commerce is still dragging. Investors should have the right expectations when investing in the stock. 10 stocks we like better than Alibaba Group › Alibaba (NYSE: BABA) was once the crown jewel of China's internet economy. Today, it's more complicated. The e-commerce giant has faced regulatory crackdowns, weakening Chinese consumer marketing, and fierce competition from fast-moving rivals like Pinduoduo and Douyin. Yet beneath the surface, Alibaba is quietly undergoing a significant transformation -- one that could define its next decade. Where to invest $1,000 right now? Our analyst team just revealed what they believe are the 10 best stocks to buy right now. Continue » For investors considering the stock today, here's one green flag that signals long-term potential, and one red flag that still casts a shadow. Green flag: AI and cloud could rewrite Alibaba's growth story Alibaba is no longer content with being just an e-commerce platform. Its most ambitious bet today is on becoming an artificial intelligence (AI)-native enterprise -- and the heart of that shift lies in Alibaba Cloud. Once seen as a lower-margin, China-centric hosting business, Alibaba Cloud has repositioned itself around artificial intelligence. At the core of this transition is its integration with Qwen -- Alibaba's open-source large language model (LLM), which significantly expands the platform's reach beyond just cloud infrastructure. Qwen itself is no lightweight. The latest version, Qwen3, rivals the performance of OpenAI's GPT-4 and Google's Gemini in several benchmark tasks. But that's just one part of the story. The most significant strategic move that Alibaba Cloud has undertaken for Qwen is to make it open-source, inviting anyone to leverage its model to build their own AI applications. This open AI strategy positions Alibaba Cloud to expand beyond China into emerging markets and Southeast Asia, especially in markets where U.S. tech dominance is weaker. As developers build on Qwen, they will naturally utilize other services offered by Alibaba. In other words, Alibaba Cloud aims to become a full-stack AI ecosystem for developers and businesses. Besides investing in Qwen, Alibaba Cloud is also doubling down on its investment in core infrastructure, aiming to invest around $50 billion in the next three years. This planned investment will exceed Alibaba's total AI and cloud spending over the past decade, demonstrating the company's commitment to becoming a leading AI cloud provider. If successful, AI and cloud computing could become Alibaba's growth driver for the next decade, just as AWS is now a key growth driver for Amazon. Red flag: Core e-commerce is still struggling to regain its past glory While AI captures investor attention, Alibaba's core revenue continues to come from domestic commerce. In fiscal year 2025 (ended March 31), this segment accounted for 45% of revenue and 113% of adjusted earnings before interest, taxes, and amortization (EBITA) -- a sign that Alibaba's profits remain heavily dependent on its e-commerce operations. Note that EBITA was 113% since other segments recorded a combined loss in 2024. But growth is sluggish. In fiscal year 2025, ended March 31, 2025, Taobao and Tmall revenue grew just 3%, as consumer sentiment in China remained soft amid a weak economic backdrop and ongoing geopolitical tensions. At the same time, Alibaba is facing intense competition from Pinduoduo's low-price strategy and Douyin's short video commerce -- both of which are quickly capturing market share. Alibaba has attempted to respond by incorporating AI into its shopping experiences and intensifying efforts to reengage merchants and users. Encouragingly, domestic e-commerce revenue grew 9% year over year in the March 2025 quarter -- a notable improvement from the full-year trend. If Alibaba can sustain its execution, it can continue to ride the tailwinds of a growing GDP per capita and a growing retail industry. Still, Alibaba has to prove it can sustain this momentum. The structural pressures -- from competition to shifts in consumer behavior -- won't disappear overnight. What does it mean for investors? Alibaba is at a crossroads. On one hand, it's laying the foundation for long-term success through open-source AI, cloud infrastructure, and international expansion. On the other hand, its dominant Chinese e-commerce business is facing challenges that may persist for some time. For investors looking for short-term upside, there are cleaner growth stories elsewhere. However, those willing to wait for the AI flywheel to turn and who believe Alibaba can navigate China's evolving economic landscape may find this to be an underappreciated opportunity. Either way, Alibaba deserves a spot on your radar. Should you invest $1,000 in Alibaba Group right now? Before you buy stock in Alibaba Group, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Alibaba Group wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $653,427!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $1,119,863!* Now, it's worth noting Stock Advisor's total average return is 1,060% — a market-crushing outperformance compared to 182% for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of August 4, 2025
CTV News
18 hours ago
- CTV News
How the atomic bombing of Nagasaki tore apart Japan's understanding of motherhood
FILE - In this Sept. 13, 1945, file photo, the Urakami Catholic Cathedral in Nagasaki, Japan, stands waste in the aftermath of the detonation of the atom bomb over a month ago over this city. (AP Photo/Stanley Troutman, Pool, File) When Kikuyo Nakamura's adult son discovered bumps on his back, she assumed it was just a rash. Still, she urged him to go to the hospital — better safe than sorry. Hiroshi, her second son, was born in 1948, three years after the U.S. dropped an atomic bomb on Nagasaki. As a survivor of the bombing, Nakamura had long feared she might pass on health problems to her children. In 2003, at age 55, Hiroshi went to the hospital. Two days passed without any word from him. Then three. Then a week. Eventually Nakamura went to the hospital, where her son told her: ''They're going to do more tests,' she told CNN. The results showed he had stage 4 leukemia –– an advanced stage of blood cancer that had spread to other parts of his body. According to Nakamura, the doctor told her that she had given her son cancer –– suggesting the radiation that caused it was passed on through breastfeeding when he was a baby. When Hiroshi died, six months later, his mother was left to believe she had essentially killed him; a thought that still haunts her more than two decades on. 'I was overwhelmed with guilt and suffering… Even now, I still believe what the doctor said, that I caused it. That guilt still lives in me,' said Nakamura, who is now 101-years old. Those who are exposed to nuclear radiation are generally urged to stop breastfeeding in the immediate aftermath of an atomic blast. But experts say there's no concrete evidence that first generation 'hibakusha' –– atomic bomb survivors of World War II –– can pass cancer-causing material to their children, years after exposure. As the 80th anniversary of the U.S. bombings of Hiroshima and Nagasaki approaches, aging survivors — some, like Nakamura, more than 100-years old — are sharing their stories of suffering and resilience, while they still can. Many of them were young women, either pregnant or of childbearing age, when the bombs fell and have lived much of their lives under a heavy shadow of fear and stigma. They were told by medical practitioners, neighbors, even friends and family that their exposure to nuclear radiation could cause them to have children with illnesses or disabilities –– if they conceived at all. Even when infertility or a child's disability had nothing to do with radiation exposure, hibakusha women often felt blamed and shunned. Those with visible scars from the blasts faced barriers to marriage. Physical wounds were harder to hide — and clearer proof of exposure. And at a time in society when a woman's worth was closely tied to marriage and motherhood, this stigma was particularly damaging. It caused a large number of women survivors –– many of whom had PTSD (post-traumatic stress disorder) –– to 'hide the fact that they were hibakusha,' according to Masahiro Nakashima, a professor of radiation studies at Nagasaki University. 'In a society like Japan — where gender discrimination and male dominance have been deeply rooted — women were especially affected by radiation,' Nakashima told CNN. Lifelong scars Radiation exposure did affect some second-generation survivors, depending on the timing of pregnancy. The embryonic period — generally ranging from weeks 5 up to 15 — is especially sensitive for brain and organ development. Women exposed to radiation during this window had a higher risk of giving birth to children with intellectual disabilities, neurological issues, and microcephaly, a condition marked by a small head and impaired brain function, according to studies from the joint Japan-U.S. Radiation Effects Research Foundation (RERF) –– a successor to the Atomic Bomb Casualty Commission formed just after World War II. Other studies showed that women hibakusha faced long-term health risks themselves. A 2012 RERF study found that radiation exposure from an atomic bomb raised cancer risk for the rest of a person's life. Solid cancer rates for women at age 70 increased by 58 per cent for every gray of radiation their bodies absorbed at age 30. A gray is a unit that measures how much radiation energy a body or object takes in. For men, solid cancer rates increased by 35 per cent. Nakamura was 21-years old and was hanging laundry outside around 11am when the bomb fell on Nagasaki on August 9, 1945. She says she was 5 kilometres (3.1 miles) from the epicentre –– a little beyond what experts call the area of 'total destruction.' The young mother saw a bright light, followed by a loud boom and a powerful gust of wind that flung her into the air. When she regained consciousness, her house was wrecked — furniture was strewn everywhere and glass shards covered the floor. She called out to her own mother, who had been helping Nakamura care for her eldest son. Relieved they weren't physically wounded, the family fled to an air raid shelter. It wasn't until the next day that Nakamura grasped the scale of destruction. Relatives living near Nagasaki University, closer to the blast, all died. Nakamura says she didn't suffer any effects of radiation exposure. She had her uterus removed four years later, and at age 70, doctors found a tumor in her abdomen, but her physicians told her neither issue was linked to the bombing, she said. The psychological trauma, however, has stayed with her ever since. Ashamed of her own exposure, she feared the stigma would also pass to her grandchildren. 'If people knew that my son died of leukemia, especially before they (my grandchildren) got married, others might not want to marry them. I made sure my children understood that. We kept it within the family and didn't tell anyone else about how he died,' Nakamura said. But encouraged by other survivors, she finally spoke publicly about her son's cancer in 2006, three years after his death. 'I received phone calls and even letters from people who heard my story. It made me realize how serious the issue of inherited health effects is in Hiroshima and Nagasaki,' she said. Even though she now knows it's unlikely she could have caused her son's cancer, she says as a mother, the feeling of guilt is a burden she'll forever carry. 'I still feel so sorry. I keep apologizing to him. I say, 'Forgive me,'' she said. The children who never followed The unique burden of hibakusha motherhood is something Mitsuko Yoshimura, now 102-years old, never got to carry. Separated from her parents and sister at a young age, she always longed for a family. She moved to Nagasaki for a good job in Mitsubishi's payroll department — just months before the U.S. dropped the bomb, turning the city into hell on earth. 'When I got out to the road, there were people with blood gushing from their heads, people with the skin peeled off their backs,' she recalled. Being just a kilometre (0.6 miles) away from the epicentre of the blast, her survival was nothing short of a miracle. In the months that followed, she stayed behind to help the injured. But her body suffered too. 'My hair fell out. Whenever I tried to comb it with my hands, strands would come out little by little,' Yoshimura said. She also regularly vomited blood for months after the blast. Still, she endured. She got married a year after the war ended. Her husband was an atomic bomb survivor, like herself, and their marriage marked a fresh start for the couple. But the child they longed for never followed. She had two miscarriages and a stillbirth. Yoshimura lives alone now; her husband having died years ago. In her home in Nagasaki, where photos of children and grandchildren might be, there are dolls — a quiet substitute for what was lost, she said. At their remarkable age, Nakamura and Yoshimura both know they don't have much longer to live. But that gives them greater urgency to educate younger generations about the toll of nuclear war. 'People really need to think carefully. What does winning or losing even bring? Wanting to expand a country's territory, wanting a country to gain more power, what exactly are people seeking from that?' Nakamura asked. 'I don't understand it. But what I do feel deeply is the utter foolishness of war,' she said. By Hanako Montgomery.
